Sophie Dimicoli‐Salazar

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini et al. · The Lancet · 2023 · 164 citations · Full text

Medicine, Hematology, Pharmacology +14

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Matteo Della Porta, Guillermo Garcia‐Manero, Valeria Santini et al. · The Lancet Haematology · 2024 · 48 citations

Medicine, Hematology, Pharmacotherapy +11

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Marie Sébert, Thomas Cluzeau, Odile Beyne Rauzy et al. · Blood · 2021 · 45 citations

Medicine, Hematology, Pharmacology +8

Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes

Laura Polivka, Marine Madrange, Stéphane Barete et al. · Journal of Allergy and Clinical Immunology · 2023 · 36 citations · Full text

Life Sciences, Genetics, Pathology +13

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

Vincent Jachiet, Olivier Kosmider, Maxime Beydon et al. · Blood · 2025 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13